Low Trough Plasma Concentrations of Nevirapine Associated with Virologic Rebounds in HIV-Infected Patients Who Switched from Protease Inhibitors
Authors:
- 1 April 2005
- journal article
- research article
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 39 (4) , 603-609
Abstract
BACKGROUND: The substitution of a nonnucleoside reverse-transcriptase inhibitor (NNRTI) for protease inhibitors (PIs) has demonstrated its suitability to maintain virologic response. However, the switch from PIs to an NNRTI could fail for a number of reasons, including NNRTI-associated toxicity and emergence of NNRTI-resistant variants. OBJECTIVE: To describe the virologic failures among 74 HIV-infected patients who switched from PIs to nevirapine. METHODS: Virologic failure was defined as any rebound of the plasma HIV-RNA (pVL) levels >1000 copies/mL on one occasion or 2 consecutive intermittent viremia episodes defined as increases of the pVL >20 copies/mL but 1000 copies/mL, nevirapine mutations and nucleoside reverse-transcriptase inhibitor mutations were found in 80% of the cases. CONCLUSIONS: The risk of virologic failure after the switch from PI to nevirapine is higher in cases of inadequate nevirapine plasma concentrations. Our data support prospective monitoring of nevirapine plasma concentrations to detect low concentrations prior to the emergence of resistance mutations.Keywords
This publication has 21 references indexed in Scilit:
- Long‐Term Efficacy and Safety of Protease Inhibitor Switching to Nevirapine in HIV‐Infected Patients with Undetectable Virus LoadClinical Infectious Diseases, 2004
- Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients with Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 2003
- Low Nevirapine Plasma Concentrations Predict Virological Failure in an Unselected HIV-1-Infected PopulationClinical Pharmacokinetics, 2003
- Does an Increase in Nevirapine Plasma Levels Cause Complete Virologic Suppression in Patients Experiencing Early Virologic Failure?HIV Research & Clinical Practice, 2002
- Low Risk of Treatment Failure after Substitution of Nevirapine for Protease Inhibitors among Human Immunodeficiency Virus–Infected Patients with Virus SuppressionThe Journal of Infectious Diseases, 2002
- Virological, Immunological, and Clinical Impact of Switching from Protease Inhibitors to Nevirapine or to Efavirenz in Patients with Human Immunodeficiency Virus Infection and Long-Lasting Viral SuppressionClinical Infectious Diseases, 2002
- Mechanism of Virologic Failure After Substitution of a Protease Inhibitor by Nevirapine in Patients With Suppressed Plasma HIV-1 RNAJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Antiretroviral Treatment Simplification With Nevirapine in Protease Inhibitor–Experienced Patients With HIV-Associated LipodystrophyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- HIV-1 Protease Inhibitors Induce an Increase of Triglyceride Level in HIV-Infected Men Without Modification of Insulin Sensitivity: A Longitudinal StudyHormone and Metabolic Research, 2000
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998